GlassScriptPhysician profile
James Michael Harrison
NPI 1669953956
$13,982.17
in general payments reported to CMS, 2019-2025
28 companies · $2,045 in 2025
The $2,045 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,108 · 2022: $2,369 · 2023: $4,199 · 2024: $3,261 · 2025: $2,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,504.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,506.96 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,204.95 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,815.20 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,725.67 | 2021-2025 | Ingrezza |
| Novo Nordisk INC | $1,077.08 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $613.31 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceuticals, INC. | $539.67 | 2021 | |
| Alkermes, INC. | $490.19 | 2022-2024 | Lybalvi, Aristada |
| Bayer Healthcare Pharmaceuticals INC. | $426.66 | 2022-2023 | |
| Glaxosmithkline, LLC. | $377.00 | 2021-2025 | Arexvy, Shingrix |
| Abbott Laboratories | $341.91 | 2023-2025 | Freestyle Libre 3, Mitraclip |
| Gilead Sciences, INC. | $246.88 | 2023-2025 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $241.07 | 2022-2023 | Austedo Xr |
| Dexcom, INC. | $240.43 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Exact Sciences Corporation | $162.54 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $124.99 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.95 | 2023 | |
| Janssen Pharmaceuticals, INC | $121.12 | 2023 | Spravato |
| Corium, LLC | $114.75 | 2023 | Azstarys |
| Amgen INC. | $105.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2022 | |
| Rgh Enterprises LLC | $92.19 | 2025 | |
| Corcept Therapeutics | $89.71 | 2024 | Korlym |
| Hikma Pharmaceuticals USA | $29.35 | 2023 | Ryaltris, Mitigare |
| Axsome Therapeutics, INC. | $20.69 | 2022 | |
| Averitas Pharma INC. | $20.67 | 2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $15.57 | 2022 | |
| Pfizer INC. | $15.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.